Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC).

Targeted oncology - 1 Mar 2013

Kobayashi Kunihiko, Hagiwara Koichi

Abstract excerpt

Before 2009, nonsmall cell lung cancer (NSCLC) was one disease entity treated by cytotoxic chemotherapy that provided a response rate of 20-35 % and a median survival time (MST) of 10-12 months. In 2004, it was found that activated mutations of the epidermal growth factor receptor (EGFR) gene were present in a subset of NSCLC and that tumors with EGFR mutations were highly sensitive to EGFR tyrosine kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 23361373
DOI: 10.1007/s11523-013-0258-9
PMCID: PMC3591525

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC).PMID 23361373Read ↗

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.Semantic proximity Read ↗

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.Semantic proximity Read ↗

Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer.Semantic proximity Read ↗

Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC.Semantic proximity Read ↗

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?Semantic proximity Read ↗

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.Semantic proximity Read ↗

Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives.Semantic proximity Read ↗

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.Semantic proximity Read ↗

Efficacy of First-Third generation EGFR inhibitor combined with chemotherapy as first-line treatment for advanced lung adenocarcinoma in a real-world settingSemantic proximity Read ↗

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.Semantic proximity Read ↗

Epidermal growth factor receptor first generation tyrosine-kinase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.